Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine

Abstract The Plasmodium falciparum Pfs230 and Pfs48/45 proteins are leading candidates for a malaria transmission-blocking vaccine (TBV). Previously, we showed that a Pfs230–Pfs48/45 fusion protein elicits higher levels of functional antibodies than the individual antigens, but low yields hampered p...

Full description

Bibliographic Details
Main Authors: Susheel K. Singh, Jordan Plieskatt, Bishwanath K. Chourasia, Vandana Singh, Karin Lövgren Bengtsson, Jenny M. Reimer, Renate C. van Daalen, Karina Teelen, Marga van de Vegte-Bolmer, Geert-Jan van Gemert, Matthijs M. Jore, Michael Theisen
Format: Article
Language:English
Published: Nature Portfolio 2021-10-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-021-00383-8

Internet

https://doi.org/10.1038/s41541-021-00383-8

Similar Items